Risk of major adverse cardiovascular events in patients initiating biologics/apremilast for psoriatic arthritis: a nationwide cohort study

Pina Vegas and her colleagues sought to assess the relative risk of MACEs in patients with PsA initiating bDMARDs or apremilast. They found that overall, the data produced overall a positive picture regarding the incidence of MACE in treatment.

In this investigation Pina Vegas and her team undertook a nationwide cohort study. This study utilised two key databases: that of the French National Health Insurance and the National hospital discharge. Their primary endpoint was the occurrence of MACE amongst the participants, an event which was defined as a combination of acute myocardial infarction and ischaemic stroke.

In addition to their main findings researchers also found that there was an increased risk of MACEs in new users of IL-12/23i and IL-17i vs TNFi in PsA. This suggests that TNFi therapy should be the first second-line therapy utilised in PsA, especially for patients with high CVD risk